

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 October 2022 (27.10.2022)



(10) International Publication Number
WO 2022/226339 A1

(51) International Patent Classification:
C07K 16/24 (2006.01) C07K 16/06 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2022/025994

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
22 April 2022 (22.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/178,938 23 April 2021 (23.04.2021) US

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors: ZHANG, Hao; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). POLOZOVA, Alla; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). FITZPATRICK, Kelly; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). ABRAMS, Kristin; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). XIANG, Dong; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). JOUBERT, Marisa; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US).

(74) Agent: NEVILLE, Katherine, L.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTI-TSLP ANTIBODY COMPOSITIONS AND USES THEREOF

(57) Abstract: The present application relates, in general, to compositions comprising anti-TSLP antibody tezepelumab and derivatives thereof having antibody quality attributes.

WO 2022/226339 A1